Gilenya

Fingolimod

THERAPY

Protocols

Before Initiation of Therapy :

First Dose :

Monitoring During Therapy :

Discontine Therapy :

Product Monograph

Specific Concerns

Contraindications :

Pregnancy :

Gilenya is teratogenic. Women of childbearing potential should be counseled on the potential for serious risk to the fetus and the need for effective contraception during, and for 2 months after treatment. Breastfeeding is discouraged while receiving and for two months after stopping Gilenya.

Vaccination :

Live vaccines should be avoided during Gilenya therapy and for 2 months after cessation. Vaccination may be less effective during and for up to two months after discontinuing treatment

Adverse Events :

Drug Interactions :